dc.contributor.author |
Aso Pérez, Ester |
dc.contributor.author |
Sánchez Pla, Alexandre |
dc.contributor.author |
Vegas Lozano, Esteban |
dc.contributor.author |
Maldonado, Rafael, 1961- |
dc.contributor.author |
Ferrer, Isidre |
dc.date |
2015 |
dc.identifier.citation |
Aso E, Sánchez-Pla A, Vegas-Lozano E, Maldonado R, Ferrer I. Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice. J Alzheimers Dis. 2015; 43(3): 977-91. DOI: 10.3233/JAD-141014 |
dc.identifier.citation |
1387-2877 |
dc.identifier.citation |
http://dx.doi.org/10.3233/JAD-141014 |
dc.identifier.uri |
http://hdl.handle.net/10230/23305 |
dc.format |
application/pdf |
dc.language.iso |
eng |
dc.publisher |
IOS Press |
dc.rights |
© IOS Press. All rights reserved |
dc.rights |
info:eu-repo/semantics/openAccess |
dc.subject |
Cannabis |
dc.subject |
Medicina |
dc.subject |
Alzheimer, Malaltia d' |
dc.title |
Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice |
dc.type |
info:eu-repo/semantics/article |
dc.type |
info:eu-repo/semantics/acceptedVersion |
dc.description.abstract |
Several recent findings suggest that targeting the endogenous cannabinoid system can be considered as a potential therapeutic approach to treat Alzheimer's disease (AD). The present study supports this hypothesis demonstrating that delta-9-tetrahydrocannabinol (THC) or cannabidiol (CBD) botanical extracts, as well as the combination of both natural cannabinoids, which are the components of an already approved cannabis-based medicine, preserved memory in AβPP/PS1 transgenic mice when chronically administered during the early symptomatic stage. Moreover, THC + CBD reduced learning impairment in AβPP/PS1 mice. A significant decrease in soluble Aβ42 peptide levels and a change in plaques composition were also observed in THC + CBD-treated AβPP/PS1 mice, suggesting a cannabinoid-induced reduction in the harmful effect of the most toxic form of the Aβ peptide. Among the mechanisms related with these positive cognitive effects, the anti-inflammatory properties of cannabinoids may also play a relevant role. Here we observed reduced astrogliosis, microgliosis, and inflammatory-related molecules in treated AβPP/PS1 mice, which were more marked after treatment with THC + CBD than with either THC or CBD. Moreover, other cannabinoid-induced effects were uncovered by a genome-wide gene expression study. Thus, we have identified the redox protein thioredoxin 2 and the signaling protein Wnt16 as significant substrates for the THC + CBD-induced effects in our AD model. In summary, the present findings show that the combination of THC and CBD exhibits a better therapeutic profile than each cannabis component alone and support the consideration of a cannabis-based medicine as potential therapy against AD. |
dc.description.abstract |
This study was supported by grants from the Agrupació Mútua Foundation (XVII Award in the Elderly Field, to IF), Mutua Madrileña Foundation (IF), and BESAD-P project, CIBERNED, Instituto Carlos III (IF). |